Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132117 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT02132117: Completed Phase 3 study, sponsored by Allergan.
NCT02132117 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 445 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02132117, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Primary Outcome
The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redne
Interventions
- DRUG Oxymetazoline HCL Cream 1.0%
- DRUG Vehicle to Oxymetazoline HCL Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
What the finished NCT02132117 record still lists
NCT02132117 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxymetazoline HCL Cream 1.0% is the first listed.
NCT02132117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02132117 about?
NCT02132117 is a clinical study titled "Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea". This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT02132117?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02132117?
The interventions under investigation include: Oxymetazoline HCL Cream 1.0% (DRUG), Vehicle to Oxymetazoline HCL Cream (DRUG).
Who is sponsoring clinical trial NCT02132117?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02132117's enrollment target sits among peer trials
445 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia